Coloplast is a medical technology company specializing in intimate healthcare solutions. The company operates through five business segments: Ostomy Care, providing ostomy bags and supporting products; Continence Care, offering intermittent catheters and collecting devices; Interventional Urology, supplying implants, slings, and surgery tools; Bowel Care, featuring transanal irrigation systems; and Wound & Tissue Repair, which includes wound dressings and biologics. Additionally, the company provides Voice and Respiratory Care products such as voice prostheses, heat and moisture exchangers, tubes, and adhesives. Coloplast serves patients with intimate healthcare needs and supports healthcare professionals through its Coloplast Care and Coloplast Professional services, which include practical support, education, and tools for managing daily life and clinical care.

Summarised from the company's own disclosures

Industry Medical Devices Homepage coloplast.com
Sector Healthcare IR page coloplast.com/investor-relations
Tags
ostomy care, continence care, interventional urology, bowel care, wound care, voice prostheses, respiratory care, intimate healthcare, Coloplast Care, Coloplast Professional
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 21.3%
ROI 10.2%
ROIC 21.6%
Profit margin 13.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) -8.2%
Quality  
Profitable Yes
Margin expanding No
Buying back stock —
Diluting (TTM) —
Debt/Equity 120.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 14
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 27.874B 27.03B 24.5B 22.579B 19.426B
Net profit 3.636B 5.052B 4.783B 4.706B 4.825B

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Coloplast opens new factory in Portugal to support global growth Bull 2 Bear 0 Product/operations

Coloplast today inaugurates its largest manufacturing site to date, a two-floor 50,000 m2 facility in Felgueiras, Portugal, expanding the company’s production capacity to meet growing global demand for continence care products, while supporting the company’s long-term ambition of helping four million people worldwide.

  • Our new manufacturing site is an important milestone in our company’s mission to help those with intimate healthcare needs. We have chosen Portugal as the destination for several reasons. Most importantly, Portugal has a qualified and highly trained labour force as well as a competitive cost level. It is also important that Portugal is in Europe, where we serve most of our users today and where more and more people will be needing our products in the years to come. This destination allows us to diversify our manufacturing footprint in Europe, which is currently concentrated in Hungary. Finally, Portugal has a large supply of renewable electricity as well as an ambition to become carbon neutral by 2045, says Executive Vice President, Global Operations, Allan Rasmussen.

Production is already underway at the site, which is expected to employ more than 800 people in the region over time. The site represents an investment of around EUR 100 million.

  • Since we started planning the site in 2021, we have experienced a very constructive dialogue with the Portuguese authorities on both the national and local level. We began construction in the summer of 2024 and have, in a little more than two years, managed to finalise construction, build an organisation of more than 300 people and establish a running production. Our new Portuguese colleagues have done very well and it is thanks to them that we can now open the factory exactly as planned. We look forward to welcoming more colleagues in Felgueiras and to continue working with our partners in the region, says Frank Berg Rasmussen, Vice President, Manufacturing Portugal.

AICEP – The Portuguese Trade & Investment Agency – has played an active role in helping Coloplast establish its site in Felgueiras.

  • Coloplast’s decision to establish its largest industrial hub in Portugal is a strong vote of confidence in our country’s ability to attract and deliver strategic industrial investments. This is particularly significant in the medical devices sector, where advanced manufacturing, innovation, highly skilled talent and the highest quality standards are critical to success. This investment reinforces Portugal’s position as a competitive destination for high-value industrial projects and demonstrates our capacity to support their long-term growth. AICEP is proud to have supported Coloplast throughout this journey. We look forward to seeing this investment create skilled jobs, strengthen Portugal’s industrial ecosystem and contribute to the company’s continued international growth, says Ana Casaca, President of AICEP.

Coloplast has a global manufacturing network with high volume production sites in Hungary, China, and Costa Rica, specialised production in the US, France, Germany, Sweden, and Iceland, as well as an innovation and pilot plant in Denmark. With the new site in Portugal operational, Coloplast has sufficient production capacity to reach its targets within the current 2030 strategy period without constructing additional manufacturing sites.

The inauguration of the Coloplast Felgueiras manufacturing site takes place today on October 29th with representatives from national and local authorities, Coloplast leadership and employees celebrating the completion of the site.

General media inquiriesPeter Mønster Head of Media Relations & Corporate Content +45 4911 2623 [email protected]

On-site media contact for the inaugurationJakob Danving Nielsen Senior Communication Manager

Investors and analystsAleksandra Dimovska Vice President, Investor Relations +45 4911 2458 [email protected]

Tuesday, 3 November 2026 at 11.00 - 12.00am CETIn connection with the publication of Coloplast’s financial results for FY 2025/26, to be released same day around 07.30 am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call. The webcast of the conference call will be available during and after the event.

Coloplast will be represented by: Gavin Wood - President & CEO Anders Lonning-Skovgaard-Executive Vice President, CFO Aleksandra Dimovska - Vice President, Investor Relations Kristine Husted Munk - Senior Director, Investor Relations Nicklas Overgaard - Senior Manager, Investor Relations

WebcastFor participants who do not wish to actively participate in the Q&A session, please access the conference call as a webcast via the link below: Access the webcast here

Dial-in detailsTo actively participate in the Q&A session, please sign up ahead of the conference call on the link below to receive an email with dial-in details. Register for the conference call here

Media library

Gavin Wood

Gavin Wood

Download high resolution picture

Download

122mb

Headquarters in Humlebæk

Headquarters in Humlebæk

Download high resolution picture

Download

8.6mb

Jette Nygaard-Andersen

Jette Nygaard-Andersen

Download high resolution picture

Download

67.9mb

SenSura Mio

SenSura Mio

Download high resolution picture

Download

44.5mb

Research & development

Research & development

Download high resolution picture

Download

7.52mb

Coloplast Corporate Logo Package (Digital)

Coloplast Corporate Logo Package (Digital)

Download high resolution picture

Download

93.3kb

1 - 6 of 45 results

Prompts

Coloplast (ticker COLO-B), listed in Denmark.

ETFs Holding Coloplast

ETF Weight in ETF Shares Market value As of
BKCI 2.52% 49,902 $ 3.306M Jul 31, 2026
TLCI 1.08% 21,026 $ 1.197M Jun 30, 2026
ESIM 0.91% 2,479 $ 163.848K Jul 31, 2026
DFSI 0.03% 4,660 $ 340.852K Nov 12, 2026
NTSI 0.02% 1,763 $ 100.392K Jun 30, 2026
DFAI 0.02% 40,635 $ 2.972M Nov 12, 2026
AVDE 0.01% 34,649 $ 2.582M Nov 16, 2026
DFAX 0.00% 4,643 $ 339.608K Nov 12, 2026
DIHP 0.00% 1,892 $ 138.389K Nov 12, 2026
DFIC 0.00% 1,498 $ 109.57K Nov 12, 2026
AVSD 0.00% 191 $ 14.232K Nov 16, 2026